EDAP starts trial of high-intensity focused ultrasound in liver cancer
This article was originally published in Clinica
French therapeutic ultrasound specialist EDAP TMS is to start a phase I study of high-intensity focused ultrasound (HIFU) in metastatic liver cancer. The trial, which has been authorised by the French regulatory organisation AFSSAPS, will treat 20 patients over the next six months with a HIFU device designed to destroy hepatic metastases while preserving surrounding tissues. The Lyon-based company hopes the device will expand the number of patients eligible for surgery and increase survival rates. EDAP jointly developed the system with the research institute INSERM 556 Unit and cancer hospital Centre Leon Berard, both also based in Lyon. EDAP already markets a similar device for localised prostate cancer, Ablatherm-HIFU, in Europe; it is being evaluated in the US.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.